Healthcare / Drug Manufacturers - GeneralNSE
$1067.80
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-2.0B · quality 53.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
64/100
B
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$49.2B
P/E
40.5x
↑EV/EBITDA
23.1x
↑ROE
12.4%
↑Gross Margin
60.2%
↑Debt/Equity
0.37
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+161.6%
FCF CAGR
—
FCF margin
-32.0%
FCF / Net income
-1.76x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $6.33B · net income $1.15B · FCF $-2.03B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $6.33B | $6.33B | $3.98B | $2.11B | $353.3M |
| Net Income | $1.15B | $1.15B | $585.7M | $314.5M | $84.3M |
| EBITDA | $2.15B | $2.15B | $1.09B | $434.6M | $160.5M |
| EPS | 26.39 | 26.39 | 16.12 | 6.83 | 1.83 |
| Gross Margin | 60.2% | 60.2% | 54.6% | 47.3% | 63.9% |
| Operating Margin | 21.7% | 21.7% | 18.3% | 15.1% | 30.8% |
| Net Margin | 18.2% | 18.2% | 14.7% | 14.9% | 23.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.37 | 0.37 | 0.40 | 1.26 | 1.38 |
| Current Ratio | 1.92 | 1.92 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-2.03B | $-2.03B | $-2.03B | $-775.3M | $-483.6M |
| Returns | |||||
| ROE | 12.4% | 12.4% | 7.4% | 15.4% | 18.5% |
| Valuation | |||||
| P/E | 40.54 | 40.54 | 32.99 | — | — |
| EV/EBITDA | 23.05 | 23.05 | 19.66 | — | — |
| P/B | 5.00 | 5.00 | 2.46 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 58.9% | 58.9% | 88.9% | 496.7% | — |
| EPS Growth | 63.7% | 63.7% | 136.1% | 272.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
53.1%
EPS terminal req.
$94.75
Spread vs growth
10.6%
5Y implied EPS CAGR
34.1%
EPS terminal req.
$114.65
Spread vs growth
29.6%
10Y implied EPS CAGR
21.5%
EPS terminal req.
$184.64
Spread vs growth
42.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+106.0%
Start / end P/E
32.2x → 40.5x
EPS bridge
16.12 → 26.39
Residual
+16.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.